ITRI vs ACLX vs REZI vs LEGN vs FATE

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

5% revenue growth year-over-year, versus -79. 4% for Arcellx, Inc. (ACLX). Itron, Inc. (ITRI) offers the better valuation at 12. 5x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate Resideo Technologies, Inc. (REZI) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Resideo Technologies, Inc.

is actually cheaper at 13. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Arcellx, Inc.

(ACLX) delivered a total return of +584. 9%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: ACLX returned +584. 9% versus LEGN's -22. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcellx, Inc.

(ACLX) is the lower-risk stock at -0. 34β versus Resideo Technologies, Inc. 's 2. 27β — meaning REZI is approximately -773% more volatile than ACLX relative to the S&P 500. On balance sheet safety, Arcellx, Inc. (ACLX) carries a lower debt/equity ratio of 24% versus 109% for Resideo Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

5% versus -79. 4% for Arcellx, Inc. (ACLX). On earnings-per-share growth, the picture is similar: Fate Therapeutics, Inc. grew EPS 29. 9% year-over-year, compared to -718. 0% for Resideo Technologies, Inc.. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Itron, Inc.

(ITRI) is the more profitable company, earning 12. 7% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 12. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ITRI leads at 13. 5% versus -22. 2% for FATE. At the gross margin level — before operating expenses — ACLX leads at 70. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Resideo Technologies, Inc.

(REZI) trades at 13. 1x forward P/E versus 118. 1x for Legend Biotech Corporation — 105. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FATE: 1525. 5% to $39. 50.

In this comparison, REZI (0.

6% yield) pays a dividend. ITRI, ACLX, LEGN, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Arcellx, Inc.

(ACLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 34), +584. 9% 10Y return). Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACLX: +584. 9%, FATE: +40. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ITRI (Technology) and ACLX (Healthcare) and REZI (Industrials) and LEGN (Healthcare) and FATE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ITRI is a small-cap deep-value stock; ACLX is a small-cap quality compounder stock; REZI is a small-cap quality compounder stock; LEGN is a small-cap high-growth stock; FATE is a small-cap quality compounder stock. REZI pays a dividend while ITRI, ACLX, LEGN, FATE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.